Title:New Trends in the Pharmacological Intervention of PPARs in Obesity: Role of Natural and Synthetic Compounds
Volume: 28
Issue: 20
Author(s): Seyed Mohammad Nabavi, Kasi Pandima Devi, Sethuraman Sathya, Ana Sanches-Silva*, Listos Joanna, Sylwia Talarek, Suowen Xu, Maria Daglia, Seyed Fazel Nabavi, Samira Shirooie, Antoni Sureda*, Silvia Tejada, Maciej Banach, Ahmad Reza Dehpour and Luciano Saso
Affiliation:
- National Institute for Agricultural and Veterinary Research (INIAV), I.P., Rua dos Lagidos, Lugar da Madalena, 4485-655, Vairao, Vila do Conde,Portugal
- CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands,Spain
Keywords:
Obesity, Cardiovascular, Peroxisome proliferator–activated receptors, Endogenous and exogenous ligands,
Natural and synthetic agonists, PPAR, natural remedy for obesity.
Abstract: Obesity is a major health concern for a growing fraction of the population, as its prevalence
and related metabolic disorders are not fully understood. Over the last decade, many attempts
have been undertaken to understand the mechanisms at the basis of this condition, in
which the accumulation of fat occurring in adipose tissue leads to the pathogenesis of obesity-
related disorders. Among the most recent studies, those on Peroxisome Proliferator Activated
Receptors (PPARs) revealed that these nuclear receptor proteins acting as transcription factors,
among others, regulate the expression of genes involved in energy, lipid, and glucose
metabolisms, and chronic inflammation. The three different isotypes of PPARs, with different
tissue expression and ligand binding specificity, exert similar or overlapping functions directly
or indirectly linked to obesity. In this study, we reviewed the available scientific reports concerning
the PPARs structure and functions, especially in obesity, considering both natural and
synthetic ligands and their role in the therapy of obesity and obesity-associated disorders. On
the whole, the collected data suggest that there are both natural and synthetic compounds that
show beneficial and promising activity as PPAR agonists in chronic diseases related to obesity.
